Deoxycholic acid

(Kybella®)

Deoxycholic acid

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormInjection (subcutaneous; 10 mg/mL)
Drug ClassBile acid, cytolytic drug
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Deoxycholic acid (Kybella) is indicated for the improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. It has been found to be effective and well-tolerated, with side effects such as fibrosis, pain, erythema, and numbness being manageable.
  • The information was derived from seven systematic reviews/meta-analyses on Kybella's efficacy and safety profile.
  • Compared to placebo treatments for submental fat reduction, Kybella significantly improves all efficacy outcomes. Its positive effect on reducing submental fat and improving patient satisfaction over a 12-week period was underscored by one study.
  • Off-label use of injectable Kybella showed success rates over 85% for conditions like lipomas and xanthelasmas; however, due to the lack of high-level studies, recommendations are weak.
  • Adverse events reported were generally mild, including edema, local pain, bruising, etc., but there have been notes on severe complications like skin necrosis which require awareness during administration.
  • Studies covered adults aged between 46-49.5 years showing high levels of satisfaction post-treatment; no significant differences were noted between doses, indicating flexibility without compromising safety or effectiveness.